Related Experiment Video
Updated: Aug 18, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Thrombocytopenia, immunoglobulin treatment, and acute myocardial infarction--a case report
Guy Amit1, Tikva Yermiyahu, Harel Gilutz
1Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
Insights
Managing acute coronary syndromes in patients with severe thrombocytopenia is challenging. Careful consideration is needed before attempting to increase platelet counts for conventional treatment.
Area of Science:
- Cardiology
- Hematology
- Thrombosis
Background:
- Platelets are crucial in acute coronary syndromes (ACS).
- Platelet inhibition is a standard ACS treatment.
- Managing ACS in thrombocytopenic patients is difficult.
Observation:
- A patient with immune thrombocytopenic purpura (ITP) presented with acute myocardial infarction (AMI) and a very low platelet count.
- The patient experienced recurrent infarction after receiving immune globulin therapy.
Findings:
- The optimal management for thrombocytopenic patients with ACS remains uncertain.
- Raising platelet counts to enable conventional treatment requires extreme caution.
Implications:
- This case highlights the complexity of managing ACS in patients with profound thrombocytopenia.
- Further research is needed to establish evidence-based guidelines for this patient population.
Abstract:
Platelets play a pivotal role in the pathophysiology of the acute coronary syndromes, and platelet inhibition is a cornerstone in the management of these patients. Patients with profound thrombocytopenia who present with an acute coronary syndrome present a difficult challenge. The authors report a patient with immune thrombocytopenic purpura who presented with acute myocardial infarction despite a very low platelet count and who sustained recurrent infarction after receiving immune globulin treatment. The best management of thrombocytopenic patients with acute coronary syndromes is uncertain, but extreme caution is needed before efforts are made to raise the platelet count in order to allow conventional treatment.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Myocarditis I: Introduction
Acute Coronary Syndrome I: Introduction
Endocarditis III: Medical Management